Boston Scientific Corporation (BSX)
| Market Cap | 76.29B |
| Revenue (ttm) | 13.40B |
| Net Income (ttm) | 861.00M |
| Shares Out | 1.46B |
| EPS (ttm) | 0.60 |
| PE Ratio | 86.83 |
| Forward PE | 24.69 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 8,360,766 |
| Open | 52.78 |
| Previous Close | 52.83 |
| Day's Range | 51.54 - 53.16 |
| 52-Week Range | 38.22 - 55.38 |
| Beta | 0.78 |
| Analysts | Strong Buy |
| Price Target | 60.43 (+15.99%) |
| Earnings Date | Oct 26, 2023 |
About BSX
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through MedSurg and Cardiovascular segments. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management s... [Read more]
Financial Performance
In 2022, BSX's revenue was $12.68 billion, an increase of 6.68% compared to the previous year's $11.89 billion. Earnings were $642.00 million, a decrease of -34.82%.
Financial StatementsAnalyst Forecast
According to 21 analysts, the average rating for BSX stock is "Strong Buy." The 12-month stock price forecast is $60.43, which is an increase of 15.99% from the latest price.
News
CVS Health appoints Michael F. Mahoney to its Board of Directors
WOONSOCKET, R.I. , Sept. 21, 2023 /PRNewswire/ -- CVS Health Corporation (NYSE: CVS) has appointed Michael F.
6 Growth Stocks That Look Recession-Resistant, According to Morgan Stanley
Apple, Boston Scientific, Costco, Monster Beverage, UnitedHealth, and Colgate-Palmolive shares could still rise in the face of a consumer-spending slump, says Morgan Stanley.
Boston Scientific to acquire Relievant Medsystems for $850 million upfront, plus milestone payments
Boston Scientific Corp. BSX, +0.19% said Tuesday it has entered an agreement to acquire Relievant Medsystems Inc., a privately held medical tech company that has developed a treatment for a form of ch...
Boston Scientific to pay $850 mln upfront to buy Relievant Medsystems
Boston Scientific said on Tuesday it would buy private medical tech company Relievant Medsystems for an upfront cash payment of $850 million.
Boston Scientific Announces Agreement to Acquire Relievant Medsystems, Inc.
Acquisition intended to expand neuromodulation portfolio to provide more treatment options for people living with chronic low back pain MARLBOROUGH, Mass. , Sept. 19, 2023 /PRNewswire/ -- Boston Scien...
Investors should stick to the ‘late cycle playbook' and buy these sectors, says Morgan Stanley's Mike Wilson
Investors stumped as to where the U.S. economy is situated in the current business cycle, should be focusing on late-cycle stock sectors, which includes one that has been heating up of late.
Is Boston Scientific A Better Pick Over Altria Stock?
We believe that Boston Scientific stock (NYSE: BSX) is a better pick over Altria stock (NYSE: MO), given its better prospects.
Boston Scientific Announces FDA Approval for the Latest-Generation WATCHMAN FLX™ Pro Left Atrial Appendage Closure Device
New stroke risk reduction therapy with thromboresistant coating is designed to advance procedural performance and safety MARLBOROUGH, Mass. , Sept. 6, 2023 /PRNewswire/ -- Boston Scientific Corporatio...
Boston Scientific Announces 2023 Investor Day Meeting and Conference Call Discussing Third Quarter 2023 Results
MARLBOROUGH, Mass. , Sept. 5, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will host a meeting with the investor community to review its financial goals and long-term growth strategi...
Boston Scientific Reports Positive Results from Atrial Fibrillation Device
Boston Scientific (BSX) was the best-performing stock in the S&P 500 after the medical device maker reported positive results from a clinical trial for its system to treat patients with atrial fibrill...
ADVENT Study of the FARAPULSE™ Pulsed Field Ablation System Meets Primary Efficacy and Safety Endpoints
Noninferiority established through high treatment success, low adverse event rates Findings presented at ESC Congress 2023 and simultaneously published in The New England Journal of Medicine MARLBOROU...
Which Is A Better Buy – Boston Scientific Stock Or Abbott?
Sharpe is a measure of return per unit of risk, and high-performance portfolios can provide the best of both worlds.
Boston Scientific Receives FDA Approval for the POLARx™ Cryoablation System
First-of-its-kind expandable cryoballoon catheter advances cryoablation therapy, addresses key limitations with traditional systems MARLBOROUGH, Mass. , Aug. 8, 2023 /PRNewswire/ -- Boston Scientific ...
Stocks This Week: Hold Netflix And Sell Short Boston Scientific
Over the near term, the indices are likely to move higher into the 14th. The autumn correction will not be hard on many stocks such as Netflix.
Boston Scientific lifts annual profit forecast on heart devices strength
Boston Scientific raised its annual profit forecast for a second straight quarter on Thursday, banking on resilient demand for its cardiovascular devices as surgical procedure volumes pick up pace.
Boston Scientific stock gets a boost from profit and sales beats, raised outloook
Shares of Boston Scientific Corp. BSX, -0.02% rallied 1.9% in premarket trading Thursday, after the medical technology company beat expectations for both profit and sales, amid strength in its cardiov...
BOSTON SCIENTIFIC ANNOUNCES RESULTS FOR SECOND QUARTER 2023
MARLBOROUGH, Mass. , July 27, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.599 billion during the second quarter of 2023, growing 11.0 percent on a reported...
Boston Scientific Announces Conference Call Discussing Second Quarter 2023 Results
MARLBOROUGH, Mass. , June 28, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the second quarte...
Boston Scientific Elects Dr. Jessica L. Mega and Susan E.
MARLBOROUGH, Mass. , June 27, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announced today the election of Dr. Jessica L.
Surgical Centers, Med-Tech Stocks Up On Pent-Up Surgical Demand
After a pandemic pause, hip and knee replacements are back. Long-postponed surgeries are being rescheduled, which is bad for business at insurance companies like UnitedHealth Group Inc. NYSE: UNH, but...
What's Next For Boston Scientific Stock After Outperforming During The 2022 Inflation Shock?
The notable rise in Boston Scientific's revenues in the recent past has also contributed to the stock's outperformance.
Boston Scientific Announces Conversion Date of Series A Mandatory Convertible Preferred Stock
MARLBOROUGH, Mass. , May 30, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announced today that its Series A 5.50% Mandatory Convertible Preferred Stock (the preferred stock) will aut...
Data at Heart Rhythm 2023 Highlight Key Boston Scientific Therapies
Additional real-world outcomes further demonstrate safety, efficacy and procedural reproducibility of the FARAPULSE™ Pulsed Field Ablation System* Results from global trial of the POLARx™ Cryoablation...
Shockwave Medical, Fast Grower, In Boston Scientific's Sights?
Shockwave Medical Inc. NASDAQ: SWAV, the largest component within the iShares Russell 2000 ETF NYSEARCA: IWM, briefly cleared a cup-with-handle buy point on May 12, but reversed lower along with the b...
Boston Scientific to Participate in Bernstein's 39th Annual Strategic Decisions Conference
MARLBOROUGH, Mass. , May 15, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in Bernstein's 39th Annual Strategic Decisions Conference on Wednesday, May 31, 2023.